Crossmark

The angiotensin II type 2 receptor antagonists, PD123,319 ((S-( +)-1-[(4-(dimethylamino)-3-methylphenyl)methyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid), EMA300 (5-(2,2-diphenylacetyl)-4-[(4-methoxy-3-methylphenyl)methyl]-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-6-carboxylic acid) and EMA401 ((3S)-5-(benzyloxy)-2-(2,2-diphenylacetyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid), evoke pain relief in a varicella zoster virus-induced rat model of neuropathic pain

Crossref DOI link: https://doi.org/10.1007/s10787-025-01650-z

Published Online: 2025-02-20

Published Print: 2025-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Das, V. https://orcid.org/0000-0001-9899-6042
Lam, A. L. https://orcid.org/0009-0000-3804-6563
Smith, M. T. https://orcid.org/0000-0003-2281-3734
Funding

Funding for this research was provided by:

Australian Research Council Linkage grant (LP0668324)

Therapeutic Innovation Australia

National Collaborative Research Infrastructure Strategy (NCRIS) programme

Australian Postgraduate Award

The University of Queensland
License Information

Text and Data Mining valid from 2025-02-20

Version of Record valid from 2025-02-20
More Information

Article History

Received: 20 September 2024

Accepted: 7 January 2025

First Online: 20 February 2025

Declarations

:

: VD and ALL have no declarations of interest to disclose. In the past 3-years, MTS has collaborated with Boehringer Ingelheim Pharma GmbH & Co. KG, Argenica Therapeutics and Allay Therapeutics, on contract-funded collaborative research projects unrelated to the topic of this research. MTS is also cofounder of the UQ spin-out company, Cassowary Pharmaceuticals, aimed at discovery of novel therapeutics for the relief of chronic pain.

Document is current

Any future updates will be listed below